(Q28262360)

3

Constantine A Stratakis

0 references

André Lacroix

1

André Lacroix

0 references

Lynnette K Nieman

4

Lynnette K Nieman

0 references

Richard A Feelders

2

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline

Richard A Feelders

0 references

language of work or name

English

0 references

publication date

29 August 2015

0 references

published in

The Lancet

0 references

volume

386

0 references

issue

9996

0 references

page(s)

913-27

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Diagnosis and complications of Cushing's syndrome: a consensus statement.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

1 reference

7 January 2021

Epidemiology of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mortality and morbidity in Cushing's syndrome in New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Pros and cons of screening for occult Cushing syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Subclinical hypercortisolism among outpatients referred for osteoporosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Screening of Cushing's syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

ACTH-independent macronodular adrenal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The epidemiology and genetics of pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cushing's disease as the first clinical manifestation of multiple endocrine neoplasia type 1 (MEN1) associated with an R460X mutation of the MEN1 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

P53 gene mutation in an atypical corticotroph adenoma with Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mutations in the deubiquitinase gene USP8 cause Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Recurrent gain-of-function USP8 mutations in Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Genetic aspects of adrenocortical tumours and hyperplasias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Recurrent somatic mutations underlie corticotropin-independent Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Activating hotspot L205R mutation in PRKACA and adrenal Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Adrenocortical carcinoma: a clinician's update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Adrenocortical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Integrated genomic characterization of adrenocortical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Genetics of adrenal tumors associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

ARMC5Mutations Are a Frequent Cause of Primary Macronodular Adrenal Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Molecular and clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline and somatic mutations are associated with both primary macronodular adrenal hyperplasia and meningioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Systematic analysis of G protein-coupled receptor gene expression in adrenocorticotropin-independent macronodular adrenocortical hyperplasia identifies novel targets for pharmacological control of adrenal Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Heredity and cortisol regulation in bilateral macronodular adrenal hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Primary bimorphic adrenocortical disease: cause of hypercortisolism in McCune-Albright syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cushing's syndrome secondary to adrenocorticotropin-independent macronodular adrenocortical hyperplasia due to activating mutations of GNAS1 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Association of the M1V PRKAR1A mutation with primary pigmented nodular adrenocortical disease in two large families

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A large family with Carney complex caused by the S147G PRKAR1A mutation shows a unique spectrum of disease including adrenocortical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Carney complex with adrenal cortical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cyclical Cushing syndrome presenting in infancy: an early form of primary pigmented nodular adrenocortical disease, or a new entity?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A cAMP-specific phosphodiesterase (PDE8B) that is mutated in adrenal hyperplasia is expressed widely in human and mouse tissues: a novel PDE8B isoform in human adrenal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Massive neonatal adrenal enlargement due to cytomegaly, persistence of the transient cortex, and hyperplasia of the permanent cortex: findings in Cushing syndrome associated with hemihypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Assessment of ACTH assay variability: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Primary pigmented nodular adrenocortical disease: paradoxical responses of cortisol secretion to dexamethasone occur in vitro and are associated with increased expression of the glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Spoiled gradient recalled acquisition in the steady state technique is superior to conventional postcontrast spin echo technique for magnetic resonance imaging detection of adrenocorticotropin-secreting pituitary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Detection of adrenocorticotropin-secreting pituitary adenomas by magnetic resonance imaging in children and adolescents with cushing disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Identification of patients with Cushing's disease with negative pituitary adrenocorticotropin gradients during inferior petrosal sinus sampling: prolactin as an index of pituitary venous effluent

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The lateralization accuracy of inferior petrosal sinus sampling in 501 patients with Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The ovine corticotropin-releasing hormone stimulation test and the dexamethasone suppression test in the differential diagnosis of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A combined dexamethasone desmopressin test as an early marker of postsurgical recurrence in Cushing's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Basis of persistent and recurrent Cushing disease: an analysis of findings at repeated pituitary surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing's disease: care reality in the Munich Metropolitan Region.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Sequential hormonal changes in 21 patients with recurrent Cushing's disease after successful pituitary surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Accuracy of repeated measurements of late-night salivary cortisol to screen for early-stage recurrence of Cushing's disease following pituitary surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Early repeat surgery for persistent Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

New developments in the medical treatment of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Ketoconazole in Cushing's disease: is it worth a try?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Medical treatment of Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cabergoline monotherapy in the long-term treatment of Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Pasireotide (SOM230): development, mechanism of action and potential applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Potential role for retinoic acid in patients with Cushing's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Merits and pitfalls of mifepristone in Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Stereotactic radiosurgery for Cushing disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Clinical review: Outcome of bilateral adrenalectomy in Cushing's syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

1 reference

7 January 2021

Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Minimally invasive adrenal surgery: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Is unilateral adrenalectomy an alternative treatment for ACTH-independent macronodular adrenal hyperplasia?: Long-term follow-up of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Propranolol Therapy for Ectopic β-Adrenergic Receptors in Adrenal Cushing's Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Adrenal Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: prediction of the efficacy of beta-blockade therapy and interest of unilateral adrenalectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Whole genome expression profiling of glucose-dependent insulinotropic peptide (GIP)- and adrenocorticotropin-dependent adrenal hyperplasias reveals novel targets for the study of GIP-dependent Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Dopamine receptor expression and function in corticotroph ectopic tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cabergoline plus lanreotide for ectopic Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cushing syndrome in pediatrics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Diagnosis and treatment of pediatric Cushing's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cyclical Cushing's syndrome: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A comparison of the use of urinary cortisol to creatinine ratios and nocturnal salivary cortisol in the evaluation of cyclicity in patients with Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

A novel tool in the diagnosis and follow-up of (cyclic) Cushing's syndrome: measurement of long-term cortisol in scalp hair

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Adrenal disease in pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cushing's syndrome during pregnancy: personal experience and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Usefulness of salivary cortisol in the diagnosis of hypercortisolism: comparison with serum and urinary cortisol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mortality in Cushing's syndrome: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Multisystem morbidity and mortality in Cushing's syndrome: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Long-term mortality after transsphenoidal surgery for Cushing disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

The burden of Cushing's disease: clinical and health-related quality of life aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Ambulatory blood pressure monitoring-derived short-term blood pressure variability is increased in Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Cognitive function and cerebral assessment in patients who have Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Neuropsychiatric disorders in Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Impaired decision-making and selective cortical frontal thinning in Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Small cerebellar cortex volume in patients with active Cushing's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Quality of life and other outcomes in children treated for Cushing syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

Quality of life in patients after long-term biochemical cure of Cushing's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

1 reference

7 January 2021

Approach to the patient with possible Cushing's syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2961375-1

7 January 2021

10.1016/S0140-6736(14)61375-1

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

26004339

1 reference

Consolidated OpenCitations Corpus – April 2017